Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 16, 2022; 10(8): 2569-2576
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2569
Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature
Michael Au, Nikola Mitrev, Rupert W Leong, Viraj Kariyawasam
Michael Au, Department of Gastroenterology and Hepatology, Blacktown and Mt Druitt Hospitals, Western Sydney Local Health District, Sydney 2148, New South Wales, Australia
Michael Au, Viraj Kariyawasam, Blacktown Clinical School, Western Sydney University, Blacktown 2148, New South Wales, Australia
Nikola Mitrev, Department of Gastroenterology and Hepatology, Blacktown Hospital, Western Sydney Local Health District, Blacktown 2148, New South Wales, Australia
Rupert W Leong, Endoscopy Department and Inflammatory Bowel Disease Service, Concord Hospital, Sydney 2137, New South Wales, Australia
Rupert W Leong, Concord Clinical School, University of Sydney, Sydney 2137, New South Wales, Australia
Viraj Kariyawasam, Inflammatory Bowel Disease Service, Blacktown Hospital, Western Sydney Local Health District, Blacktown 2148, New South Wales, Austria
Author contributions: Au M compiled data, reviewed records, performed literature review, and wrote first draft; Mitrev N and Kariyawasam V reviewed records, reviewed literature, and reviewed draft; Leong RW reviewed records.
Informed consent statement: All involved persons (subjects or legally authorised representative) gave their informed consent prior to study inclusion.
Conflict-of-interest statement: Dr Rupert W Leong is currently serving on the advisory boards of AbbVie, Aspen, BMS, Celgene, Chiesi, Ferring, Glutagen, Hospira, Janssen, MSD, Novartis, Pfizer, and Takeda. The authors declare no other conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michael Au, MBBS, Doctor, Department of Gastroenterology and Hepatology, Blacktown and Mt Druitt Hospitals, Western Sydney Local Health District, Blacktown and Mt Druitt Hospitals, Sydney 2148, New South Wales, Australia. michael.au@my.jcu.edu.au
Received: September 1, 2021
Peer-review started: September 1, 2021
First decision: November 7, 2021
Revised: November 21, 2021
Accepted: February 10, 2022
Article in press: February 10, 2022
Published online: March 16, 2022
Processing time: 190 Days and 7.9 Hours
Core Tip

Core Tip: This paper describes the use of two biologics for the treatment of Crohn's disease and multiple sclerosis. Only a few papers have reported the safety and efficacy of these treatments due to inherent concerns regarding immunosuppression, infection, and malignancy. We present the case of a patient who was safely treated with vedolizumab and ocrelizumab. The combination of biologics may be a safe and effective treatment for immune-mediated diseases.